ARCHIVES

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

This article is from The Cancer Letter archive.

Vol. 26 No. 12 | December 26, 2003

Download PDF Visit The Full Archive

Related Articles

NCI, DCT Board Cool Toward AMA, ACOS, VA Role In Clinical Trials

March 3, 1989

Carmona’s Term as Surgeon General Expires.

August 4, 2006

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

December 28, 2012

Toxic Wastes And Cancer Linked; NCI Data Questioned In Bay Study

December 13, 1985

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 23, 1998

NCI CTEP: Approved Trials For The Month of October

October 28, 2011